Breast CancerPhase 3NCT01120184
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)
A Phase 3 study testing docetaxel, paclitaxel and pertuzumab in people with Breast Cancer, run by Hoffmann-La Roche at 257 sites in 38 countries.
Trial summary
This randomized, 3-arm, multicenter, phase III study will evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) with pertuzumab or trastuzumab emtansine (T-DM1) with pertuzumab-placebo (blinded for pertuzumab), versus the combination of trastuzumab (Herceptin) plus taxane (docetaxel or paclitaxel) in… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Breast Cancer
- What is being tested?
- docetaxel, paclitaxel and pertuzumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,095 participants
- Where
- 257 sitesin 38 countries
- Study dates
- 31 Jul 2010to 16 Sep 2016
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult participants >/=18 years of age
- HER2-positive breast cancer
- Histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease, and be a candidate for chemotherapy. Participants with locally advanced disease must have recurrent or progressive disease, which must not be amenable to resection with curative intent.
- Participants must have measurable and/or non-measurable disease which must be evaluable per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
- Adequate organ function as determined by laboratory results
Who cannot join
- History of prior (or any) chemotherapy for metastatic breast cancer or recurrent locally advanced disease
- An interval of <6 months from the last dose of vinca-alkaloid or taxane cytotoxic chemotherapy until the time of metastatic diagnosis
- Hormone therapy <7 days prior to randomization
- Trastuzumab therapy and/or lapatinib (neo- or adjuvant setting) <21 days prior to randomization
- Prior trastuzumab emtansine or pertuzumab therapy
Trial locations and contacts
257 sites in 38 countries.
257 sites in 38 countries
United States62 sites
The Don & Sybil Harrington Cancer Center; Department of Clinical Research
Amarillo, Texas, 79106
Anne Arundel Health System Research Instit-Annapolis Oncology Ctr
Annapolis, Maryland, 21401
University Cancer & Blood Center, LLC; Research
Athens, Georgia, 30607
Innovative Medical Research of South Florida
Aventura, Florida, 33180
Mountain States Tumor Inst.
Boise, Idaho, 83712
Boston Medical Center
Boston, Massachusetts, 02118
Charleston Oncology, P .A
Charleston, South Carolina, 29414
Medical University of SC (MUSC)
Charleston, South Carolina, 29425
Carolinas Hem-Oncology Assoc
Charlotte, North Carolina, 28203
SCRI Tennessee Oncology Chattanooga
Chattanooga, Tennessee, 37404
Uni of Chicago
Chicago, Illinois, 60637
Oncology Hematology Care - SCRI
Cincinnati, Ohio, 45242
South Carolina Oncology Associates - SCRI
Columbia, South Carolina, 29210
Northwest Oncology/ Hematology Assoc.
Coral Springs, Florida, 33065-5701
Uni of Texas Southwestern Medical Center
Dallas, Texas, 75390-9063
Decatur Memorial Hospital
Decatur, Illinois, 62526
The Providence Regional Medical Center Everett
Everett, Washington, 98201
Sanford Roger Maris Cancer Center
Fargo, North Dakota, 58102
San Juan Oncology Associates
Farmington, New Mexico, 87401
Florida Cancer Specialists; SCRI
Fort Myers, Florida, 33901
Queens Medical Associates
Fresh Meadows, New York, 11366
West Clinic
Germantown, Tennessee, 38138
Spectrum Health Grand Rapids
Grand Rapids, Michigan, 49503
Hackensack Uni Medical Center; Northern Nj Cancer Center
Hackensack, New Jersey, 07601
Ingalls Memorial Hospital
Harvey, Illinois, 60426
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033
Carolina Oncology Specialists, PA - Hickory
Hickory, North Carolina, 28602
Cancer Research Center of Hawaii; Clinical Sciences
Honolulu, Hawaii, 96813
Uni of Texas - Md Anderson Cancer Center; Dept of Breast Medical Oncology
Houston, Texas, 77030
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202
Mayo Clinic-Jacksonville
Jacksonville, Florida, 32224
Queens Hospital Center
Jamaica, New York, 11432
Scripps Cancer Center
La Jolla, California, 92037
University of California; Moores Cancer Center
La Jolla, California, 92093
Horizon Oncology Research, Inc.
Lafayette, Indiana, 47905
Arena Oncology Associates
Lake Success, New York, 11042
Dartmouth Hitchcock Med Center
Lebanon, New Hampshire, 03756
Uni of Arkansas For Medical Sciences; Arkansas Cancer Research Center
Little Rock, Arkansas, 72204
James Graham Brown Cancer Center, University of Louisville
Louisville, Kentucky, 40202
Loyola University Med Center
Maywood, Illinois, 60153
Uni of Miami School of Medicine; Sylvester Comprehensive Cancer Center
Miami, Florida, 33136
University of Minnesota.
Minneapolis, Minnesota, 55454
Clnc L Trials & Rsch Assoc-Inc
Montebello, California, 90640
Tennessee Onc., PLLC - SCRI
Nashville, Tennessee, 37203
Vanderbilt-Ingram Cancer Ctr
Nashville, Tennessee, 37232
Cancer Inst. of New Jersey
New Brunswick, New Jersey, 08901
Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut, 06510
Icahn School of Medicine at Mount Sinai
New York, New York, 10029
Weill Medical College of Cornell Uni
New York, New York, 10065
Northern Utah Associates
Ogden, Utah, 84403
Illinois Cancer Care
Peoria, Illinois, 61615
Mayo Clinic Rochester
Rochester, Minnesota, 55902
Southern California Kaiser Permanente
San Diego, California, 92108
Breastlink Medical Group Inc
Santa Ana, California, 92705
New England Cancer Specialists
Scarborough, Maine, 04074
University of Washington
Seattle, Washington, 98195
Avera Cancer Institute
Sioux Falls, South Dakota, 57105
Mercy Clinic Cancer & Hematology
Springfield, Missouri, 65804
St. John'S Mercy Medical Center; David C. Pratt Cancer Center
St Louis, Missouri, 63141
Northwest Medical Specialties
Tacoma, Washington, 98405
Kaiser Permanente; Oncology Clinical Trials
Vallejo, California, 94589
Marion L. Shepard Cancer Center
Washington, North Carolina, 27889
Japan28 sites
Aichi Cancer Center Hospital, Breast Oncology
Aichi, 464-8681
Natl Hosp Org Shikoku; Cancer Ctr, Surgery
Ehime, 791-0280
National Hospital Organization Kyushu Cancer Center;Breast Oncology
Fukuoka, 811-1395
Gifu University Hospital; Digestive Surgery
Gifu, 501-1194
Hiroshima University Hospital; Breast Surgery
Hiroshima, 734-8551
National Hospital Organization Hokkaido Cancer Center; Breast Surgery
Hokkaido, 003-0804
Hyogo College Of Medicine; Breast And Endocrine Surgery
Hyōgo, 663-8501
Hyogo Cancer Center; Breast Surgery
Hyōgo, 673-8558
Kanazawa University Hospital; Breast Oncology
Ishikawa, 920-8641
Sagara Hospital; Breast Surgery
Kagoshima, 892-0833
Tokai University Hospital, Breast Surgery
Kanagawa, 259-1193
Kumamoto University Hospital; Breast and Endocrine Surgery
Kumamoto, 860-8556
Kumamoto City Hospital, Breast and Endocrine Surgery
Kumamoto, 862-8505
Kyoto University Hospital; Breast Surgery
Kyoto, 606-8507
Tohoku University Hospital; General Surgery
Miyagi, 980-8574
Niigata Cancer Ctr Hospital; Breast Surgery
Niigata, 951-8566
Iwate Med Univ School of Med; Surgery
Numakunai, 028-3695
Kawasaki Medical School Hospital; Breast and Thyroid Surgery
Okayama, 701-0114
National Hospital Organization Osaka National Hospital; Breast Surgery
Osaka, 540-0006
Osaka University Hospital; Breast and Endocrine Surgery
Osaka, 565-0871
Saitama Medical University International Medical Center; Medical Oncology
Saitama, 350-1298
Saitama Cancer Center, Breast Oncology
Saitama, 362-0806
Shizuoka Cancer Center; Breast Surgery
Shizuoka, 411-8777
Shizuoka General Hospital; Breast Surgery
Shizuoka, 420-8527
National Cancer Center Hospital; Medical Oncology
Tokyo, 104-0045
Toranomon Hospital; Breast and Endocrine Surgery
Tokyo, 105-8470
The Cancer Inst. Hosp. of JFCR; Breast Oncology Center
Tokyo, 135-8550
Tokyo Medical Uni. Hospital; Breast Oncology
Tokyo, 160-0023
United Kingdom16 sites
Bristol Haematology and Oncology centre
Bristol, BS2 8ED
Cambridge University Hospitals NHS Foundation Trust
Cambridge, CB2 0QQ
Royal Cornwall Hospital; Dept of Clinical Oncology
Cornwall, TR1 3LQ
The Beatson West of Scotland Cancer Centre; Cancer Clinical Trials Unit
Glasgow, G12 0YN
Leicester Royal Infirmary; Dept. of Medical Oncology
Leicester, LE1 5WW
Royal Free Hospital; Dept of Oncology
London, NW3 2QG
Guys Hospital; Management Offices
London, SE1 9RT
Royal Marsden Hospital; Dept of Med-Onc
London, SW3 6JJ
Christie Hospital; Breast Cancer Research Office
Manchester, M20 4QL
Nottingham City Hospital; Oncology
Nottingham, NG5 1PB
Peterborough City Hospital; Oncology Ward
Peterborough, PE 3 9GZ
Queen Alexandra Hospital, Portsmouth
Portsmouth, PO6 3LY
Weston Park Hospital; Cancer Clinical Trials Centre
Sheffield, S10 2SJ
Southampton General Hospital; Somers Cancer Research Building
Southampton, SO16 6YD
Uni Hospital of North Staffordshire; Staffordshire Oncology Centre
Stoke-on-Trent, ST4 6QG
Royal Marsden Hospital; Dept of Medical Oncology
Sutton, SM2 5PT
Italy13 sites
Centro Catanese Di Oncologia; Oncologia Medica
Catania, Sicily, 95126
Campus Universitario S.Venuta; Centro Oncologico T.Campanella
Catanzaro, Calabria, 88100
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
Meldola, Emilia-Romagna, 47014
Ospedale Papardo- Piemonte;Oncologia Medica
Messina, Sicily, 98158
Istituto Europeo Di Oncologia
Milan, Lombardy, 20141
A.O. Universitaria Policlinico Di Modena; Ematologia
Modena, Emilia-Romagna, 41124
Fondazione Salvatore Maugeri
Pavia, Lombardy, 27100
Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica
Perugia, Umbria, 06156
Ospedale Misericordia E Dolce; Oncologia Medica
Prato, Tuscany, 59100
Arcispedale Santa Maria Nuova; Oncologia
Reggio Emilia, Emilia-Romagna, 42100
Ospedale Degli Infermi; Divisione Di Oncologia
Rimini, Emilia-Romagna, 47900
IRCCS Istituto Clinico Humanitas; Oncologia
Rozzano (MI), Lombardy, 20089
Azienda Ospedaliero-Universitaria Dipartimento Interaziendale Di Oncologia
Udine, Friuli Venezia Giulia, 33100
France12 sites
HOPITAL JEAN MINJOZ; Oncologie
Besançon, 25030
Centre Jean Perrin; Hopital De Jour
Clermont-Ferrand, 63011
Centre Oscar Lambret; Senologie
Lille, 59020
Institut Paoli Calmettes; Oncologie Medicale
Marseille, 13273
Institut régional du Cancer Montpellier
Montpellier, 34298
Centre D'Oncologie de Gentilly; Oncology
Nancy, 54100
Institut Curie; Oncologie Medicale
Paris, 75231
Hopital Saint Louis; Service Onco Thoracique
Paris, 75475
HOPITAL TENON; Cancerologie Medicale
Paris, 75970
Chu La Miletrie; Radiotherapie
Poitiers, 86021
Centre Rene Huguenin; ONCOLOGIE GENETIQUE
Saint-Cloud, 92210
Institut de Cancerologie de La Loire; Radiotherapie
Saint-Priest-en-Jarez, 42271
Spain11 sites
Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología
A Coruña, 15006
Hospital del Mar; Servicio de Oncologia
Barcelona, 08003
Hospital General Universitario de Elche; Servicio de Oncologia
Elche, Alicante, 03203
Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia
Jaén, 23007
Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
Madrid, 28007
Hospital Universitario 12 de Octubre; Servicio de Oncologia
Madrid, 28041
Hospital Universitario La Paz; Servicio de Oncologia
Madrid, 28046
Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia
Málaga, 29010
Hospital Univ Vall d'Hebron; Servicio de Oncologia
Sant Andreu de la Barca, Barcelona, 08740
Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia
Santiago de Compostela, LA Coruña, 15706
Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
Valencia, 46010
Germany10 sites
Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum
Essen, 45136
Universitätsklinikum Halle (Saale); Universitätsklinik Und Poliklinik Für Gynäkologie
Halle, 06120
Facharztzentrum Eppendorf, Studien GbR
Hamburg, 20249
MVZ Onko Medical GmbH Hannover, Ralf Lohse (Geschäftsführer)
Hanover, 30177
Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg
Heidelberg, 69120
Universitätsklinikum Magdeburg; Frauenheilkunde & Geburtshilfe
Magdeburg, 39108
Universitätsmedizin Mainz; Klinik u. Poliklinik f. Geburtshilfe u. Frauenheilkunde
Mainz, 55131
Mühlenkreiskliniken; Johannes Wesling Klinikum Minden; Klinik für Frauenheilkunde und Geburtshilfe
Minden, 32429
Rotkreuzklinikum München; Frauenklinik
München, 80637
Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie
Trier, 54290
Russia10 sites
Ivanovo Regional Oncology Dispensary
Ivanovo, 153040
Clinical Oncology Dispensary of Ministry of Health of Tatarstan
Kazan', Tatarstan Republic, 420029
Moscow city oncology hospital; #62 of Moscow Healthcare Department
Moscow, Moscow Oblast, 143423
Blokhin Cancer Research Center; Combined Treatment
Moskva, Moscow Oblast, 115478
State Budget Institution of Healthcare of Stavropol region Pyatigorsk Oncology Dispensary
Pyatigorsk, Stavropol Kray, 357502
Ryazan State Medical University Named after I.P.Pavlov
Ryazan, Ryazan Oblast, 390026
SBI of Healthcare Samara Regional Clinical Oncology Dispensary
Samara, 443031
SBI of Healthcare of Stavropol region Stavropol Regional Clinical Oncology Dispensary
Stavropol, 355045
Tula Regional Oncology Dispensary
Tula, 300053
GUZ Vladimir Regional Clinical Oncological Dispensary
Vladimir, 600009
Brazil8 sites
Clinica de Neoplasias Litoral
Itajaí, Santa Catarina, 88301-220
Liga Norte Riograndense Contra O Câncer
Natal, Rio Grande do Norte, 59040150
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, 90040-373
Clinica de Oncologia de Porto Alegre - CliniOnco
Porto Alegre, Rio Grande do Sul, 90430-090
Hospital Sao Lucas - PUCRS
Porto Alegre, Rio Grande do Sul, 90610-000
*X*Instituto Nacional do Cancer - INCA
Rio de Janeiro, Rio de Janeiro, 20560-120
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, 01246-000
Hospital Perola Byington
São Paulo, São Paulo, 01317-000
Mexico6 sites
Centro de Investigacion; Clinica Del Pacifico
Acapulco de Juárez, Guerrero, 39670
Centenario Hospital Miguel Hidalgo
Aguascalientes, 20230
Centro Universitario Contra El Cancer
Monterrey, Nuevo León, 64020
Oaxaca Site Management Organization
Oaxaca City, Oaxaca, 68000
Hospital Privado San Jose; Oncologia
Obregón, Sonora, 85000
Centro Oncológico Estatal; ISSSEMYM Oncología
Toluca, 50180
Thailand6 sites
National Cancer Inst.
Bangkok, 10400
Rajavithi Hospital; Division of Medical Oncology
Bangkok, 10400
Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc
Bangkok, 10400
Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology
Bangkok, 10700
Maharaj Nakorn Hospital; Internal Medicine
Chiang Mai, 50200
Songklanagarind Hospital; Department of Oncology
Songkhla, 90110
Australia5 sites
Royal Adelaide Hospital; Oncology
Adelaide, South Australia, 5000
Wesley Medical Centre; Clinic For Haematology and Oncology
Auchenflower, Queensland, 4066
Peter Maccallum Cancer Institute; Medical Oncology
Melbourne, Victoria, 3000
Mater Misericordiae Hospital; Chemotherapy Cottage
Sydney, New South Wales, 2060
Calvary Mater Newcastle; Medical Oncology
Waratah, New South Wales, 2298
Poland5 sites
Centrum Onkologii;Im. Franciszka Lukaszczyka;Onkologii
Bydgoszcz, 85-796
Medical University of Gdansk
Gdansk, 80-952
Centrum Onkologii, Instytut, Klinika Chemioterapii; Oddzial Chemoterapii
Krakow, 31-115
COZL Oddzial Onkologii Klinicznej z pododdzialem Chemioterapii Dziennej
Lublin, 20-090
Cent.Onkologii-Instytut im. M. S-Curie, Klinika Now. Piersi i Chirurgii Rekon
Warsaw, 02-781
South Korea5 sites
Seoul National University Bundang Hospital; Hematology Medical Oncology
Gyeonggi-do, 463-707
Seoul National Uni Hospital; Dept. of Internal Medicine/Hematology/Oncology
Seoul, 03080
Samsung Medical Centre; Division of Hematology/Oncology
Seoul, 135-710
Asan Medical Center, Uni Ulsan Collegemedicine; Dept.Internal Medicine / Divisionhematology/Oncology
Seoul, 138-736
Korea University Guro Hospital; Oncology
Seoul, 152-703
Canada4 sites
Cross Cancer Institute; Clinical Trials
Edmonton, Alberta, T6G 1Z2
CHU de Québec ? Hôpital du Saint-Sacrement / ONCOLOGY
Québec, G1S 4L8
Cuse - Centre Universitaire De Sante; Site Fleurimont
Sherbrooke, Quebec, J1H 5N4
North York General Hospital
Toronto, Ontario, M2J 1V1
Colombia4 sites
Clinica del Country
Bogotá, 11001
Instituto Colombiano Para El Avance De La Medicina: Icamedic
Bucaramanga
Centro Medico Imbanaco
Cali
Instituto Cancerologico de Nariño
Pasto
Czechia4 sites
Masarykuv onkologicky ustav
Brno, 656 53
Fakultni nemocnice Olomouc; Onkologicka klinika
Olomouc, 779 00
Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika
Prague, 128 08
Fakultni Nemocnice Na Bulovce; Ustav Radiacni Onkologie
Prague, 180 00
Hungary4 sites
Szent Margit Hospital; Dept. of Oncology
Budapest, 1032
Semmelweis Egyetem Onkologiai Központ
Budapest, 1083
Semmelweis Egyetem Aok; Iii.Sz. Belgyogyaszati Klinika
Budapest, 1125
Pécsi Tudományegyetem; Klinikai Központ Onkoterápiás Intézet
Pécs, 7623
Taiwan4 sites
Changhua Christian Hospital; Hematology-Oncology
Changhua, 500
Kaohsiung Medical Uni Chung-Ho Hospital; Dept of Surgery
Kaohsiung City, 807
National Taiwan Uni Hospital; Dept of Oncology
Taipei, 100
Tri-Service General Hospital; Hematology and Oncology
Taipei, 114
Turkey (Türkiye)4 sites
Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology
Adana, 01230
Cukurova Uni Faculty of Medicine; Medical Oncology
Adana, 01330
Gazi Uni Medical Faculty Hospital; Oncology Dept
Ankara, 06500
Ege Uni Medical Faculty Hospital; Oncology Dept
Izmir, 35100
Belgium3 sites
Cliniques Universitaires St-Luc
Brussels, 1200
Clinique Ste-Elisabeth
Namur, 5000
Sint Augustinus Wilrijk
Wilrijk, 2610
Greece3 sites
Alexandras General Hospital of Athens; Oncology Department
Athens, 115 28
Univ General Hosp Heraklion; Medical Oncology
Heraklion, 711 10
University Hospital of Larissa; Oncology
Larissa
Malaysia3 sites
Pantai Hospital Kuala Lumpur; Dept of Oncology & Radiotherapy
Kuala Lumpur, FED. Territory of Kuala Lumpur, 59100
Sunway Medical Centre
Kuala Selangor, Selangor, 46150
Beacon International Specialist Centre
Petaling Jaya, Selangor, Selangor, 46050
Peru3 sites
Hospital Nacional Carlos Alberto Seguin Escobedo-Essalud; Oncology & Haemathology
Arequipa, 04001
Hospital Nacional Edgardo Rebagliati Martins; Oncologia
Lima, 11
Unidad de Investigacion Oncologia Clinica ? Piura; Unidad de Oncología Clínica
Piura, 20011
Romania3 sites
Coltea Hospital; Oncology
Bucharest
Cluj Clinical County Hospital; Oncology Dept
Cluj-Napoca, 400006
Prof. Dr. I. Chiricuta Institute of Oncology
Cluj-Napoca, 400015
Switzerland3 sites
Kantonsspital Baden; Medizinische Klinik, Onkologie
Baden, 5404
Universitaetsspital Basel; Onkologie
Basel, 4031
Kantonsspital Graubünden Medizin Onkologie; Onkologie und Hämatologie
Chur, 7000
Argentina2 sites
Fundación Investigar
Buenos Aires, 1025
Centro Medico San Roque
San Miguel de Tucumán, T4000IAK
Austria2 sites
Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.
Salzburg, 5020
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie
Vienna, 1090
Bosnia and Herzegovina2 sites
University Clinical Centre of the Republic of Srpska
Banja Luka, 78000
Clinic of Oncology, University Clinical Center Sarajevo
Sarajevo, 71000
Guatemala2 sites
Centro Oncológico Sixtino / Centro Oncológico SA
Guatemala City, 01010
Grupo Angeles
Guatemala City, 01015
New Zealand2 sites
Auckland city hospital; Auckland Regional Cancer Centre and Blood Service
Auckland, 1023
Waikato Hospital; Regional Cancer Center
Hamilton
Philippines2 sites
Cebu Cancer Institute; Perpetual Succour Hospital
Cebu City, 6000
Cardinal Santos Medical Center
San Juan City, 1502
North Macedonia1 site
Private Health Organization Acibadem Sistina Hospital
Skopje, 1000
Sweden1 site
Skånes Universitetssjukhus; Kliniska Forskningsenheten Onkologimottagning medicinsk behandling
Malmö, 200 25
The Bahamas1 site
Oncology Consultants Limited
Nassau, 09311
About this study
Official title: A Randomized, 3 Arm, Multicenter, Phase III Study to Evaluate the Efficacy and the Safety of T-DM1 Combined With Pertuzumab or T-DM1 Combined With Pertuzumab-Placebo (Blinded for Pertuzumab), Versus the Combination of Trastuzumab Plus Taxane, as First Line Treatment in HER2 Positive Progressive or Recurrent Locally Advanced or Metastatic Breast Cancer
This randomized, 3-arm, multicenter, phase III study will evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) with pertuzumab or trastuzumab emtansine (T-DM1) with pertuzumab-placebo (blinded for pertuzumab), versus the combination of trastuzumab (Herceptin) plus taxane (docetaxel or paclitaxel) in participants with HER2-positive progressive or recurrent locally advanced or previously untreated metastatic breast cancer. Participants will be randomized to 1 of 3 treatment arms (Arms A, B or C). Arm A will be open-label, whereas Arms B and C will be blinded.
- Conditions
- Breast Cancer
- Being tested
- docetaxel, paclitaxel, pertuzumab, pertuzumab-placebo, trastuzumab [Herceptin]
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
docetaxelDrug
75 mg/m2 or 100 mg/m2 intravenously every 3 weeks for a minimum of 6 cycles.
paclitaxelDrug
80 mg/m2 intravenously weekly for a minimum of 18 weeks
pertuzumabDrug
840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles
pertuzumab-placeboDrug
840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles
trastuzumab [Herceptin]Drug
trastuzumab [Herceptin] doses when administered with docetaxel: 8 mg/kg intravenously on cycle 1 followed by 6 mg/kg every 3 weeks in subsequent cycles or trastuzumab (Herceptin) doses when administered with paclitaxel: 4 mg/kg intravenously on day 1 of cycle 1 followed by 2 mg/kg weekly starting on day 8 of cycle 1.
trastuzumab emtansineDrug
3.6 mg/kg intravenously every 3 weeks
| Study group | Role | What they receive |
|---|---|---|
| Trastuzumab + Taxane (docetaxel or paclitaxel) | Experimental | Not described Receives: Drug: docetaxel; Drug: paclitaxel; Drug: trastuzumab [Herceptin] |
| Trastuzumab emtansine + pertuzumab | Experimental | Not described Receives: Drug: pertuzumab; Drug: trastuzumab emtansine |
| Trastuzumab emtansine + pertuzumab placebo | Experimental | Not described Receives: Drug: pertuzumab-placebo; Drug: trastuzumab emtansine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With Death or Disease Progression According to Independent Review Facility (IRF) Assessment
Tumor assessments were performed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, using radiographic images submitted to the IRF up to and including the confirmatory tumor assessment 4 to 6 weeks after study drug discontinuation. Disease progression was defined as a greater than or equal to (≥) 20 percent (%) and 5-millimeter (mm) increase in sum of diameters of target lesions, taking as reference the smallest sum obtained during the study, or appearance of new lesion(s). The percentage of participants with death or disease progression was calculated as [number of participants with event divided by the number analyzed] multiplied by 100.
Measured: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
Progression-Free Survival (PFS) According to IRF Assessment
Tumor assessments were performed according to RECIST version 1.1, using radiographic images submitted to the IRF up to and including the confirmatory tumor assessment 4 to 6 weeks after study drug discontinuation. PFS was defined as the time from randomization to first documented disease progression or death from any cause. Disease progression was defined as a ≥20% and 5-mm increase in sum of diameters of target lesions, taking as reference the smallest sum obtained during the study, or appearance of new lesion(s). Median duration of PFS was estimated using Kaplan-Meier analysis, and corresponding confidence intervals (CIs) were computed using the Brookmeyer-Crowley method.
Measured: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
Secondary outcomes (37)
Percentage of Participants Who Died Prior to Clinical Cutoff
The percentage of participants who died prior to clinical cutoff was calculated as [number of participants with event divided by the number analyzed] multiplied by 100.
Measured: Up to 70 months from randomization until clinical cutoff of 15-May-2016 (every 3 months until death, loss to follow-up, withdrawal, or study termination)
Overall Survival (OS) at Clinical Cutoff
OS was defined as the time from randomization to death from any cause. Median duration of OS was estimated using Kaplan-Meier analysis, and corresponding CIs were computed using the Brookmeyer-Crowley method.
Measured: Up to 70 months from randomization until clinical cutoff of 15-May-2016 (every 3 months until death, loss to follow-up, withdrawal, or study termination)
Percentage of Participants With Death or Disease Progression According to Investigator Assessment
Tumor assessments were performed by the investigator according to RECIST version 1.1. Disease progression was defined as a ≥20% and 5-mm increase in sum of diameters of target lesions, taking as reference the smallest sum obtained during the study, or appearance of new lesion(s). The percentage of participants with death or disease progression was calculated as [number of participants with event divided by the number analyzed] multiplied by 100.
Measured: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
PFS According to Investigator Assessment
Tumor assessments were performed by the investigator according to RECIST version 1.1. PFS was defined as the time from randomization to first documented disease progression or death from any cause. Disease progression was defined as a ≥20% and 5-mm increase in sum of diameters of target lesions, taking as reference the smallest sum obtained during the study, or appearance of new lesion(s). Median duration of PFS was estimated using Kaplan-Meier analysis, and corresponding CIs were computed using the Brookmeyer-Crowley method.
Measured: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
Percentage of Participants Experiencing Treatment Failure
Treatment failure was defined as the discontinuation of all study medications in the treatment arm for any reason including disease progression, treatment toxicity, death, physician decision, or participant withdrawal. The percentage of participants with treatment failure was calculated as [number of participants with event divided by the number analyzed] multiplied by 100.
Measured: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014
Time to Treatment Failure (TTF)
Treatment failure was defined as the discontinuation of all study medications in the treatment arm for any reason including disease progression, treatment toxicity, death, physician decision, or participant withdrawal. TTF was defined as the time from randomization to treatment failure. Median TTF was estimated using Kaplan-Meier analysis, and corresponding CIs were computed using the Brookmeyer-Crowley method.
Measured: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014
One-Year Survival Rate
The percentage of participants alive at 1 year after randomization was estimated as the one-year survival rate using Kaplan-Meier analysis, and corresponding CIs were computed using Greenwood's estimate of the standard error.
Measured: From randomization until 1 year
Percentage of Participants With Grade ≥3 Adverse Events
Adverse events were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activity of daily living with inability to perform bathing, dressing and undressing, feeding self, using the toilet, taking medications but not bedridden. Grade 4: An immediate threat to life. Urgent medical intervention is required in order to maintain survival. Grade 5: Death.
Measured: Up to 50 months from randomization until clinical cutoff of 16-Sept-2014 (continuously until 28 days after last dose
Percentage of Participants Who Died at 2 Years
Measured: From randomization until 2 years
Overall Survival Truncated at 2 Years
Overall Survival truncated at 2 years was defined as the percentage of participants alive at 2 years.
Measured: From randomization until 2 years
Percentage of Participants With Grade 5 Adverse Events
Adverse events were graded according to NCI CTCAE version 4.0. Grade 5 adverse events are those events which led to death.
Measured: Up to 50 months from randomization until clinical cutoff of 16-Sept-2014 (continuously until 28 days after last dose)
Percentage of Participants With Grade 3-4 Laboratory Parameters
Laboratory results were graded according to NCI CTCAE version 4.0. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activity of daily living with inability to perform bathing, dressing and undressing, feeding self, using the toilet, taking medications but not bedridden. Grade 4: An immediate threat to life. Urgent medical intervention is required in order to maintain survival.
Measured: Day 1, 8, and 15 of Cycle 1-3 and on Day 1 of each subsequent cycle up to 50 months from randomization until clinical cutoff of 16-Sept-2014
Percentage of Participants With Decline of ≥2 Points From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status
The ECOG performance status is a scale used to quantify cancer participants' general well-being and activities of daily life. The scale ranges from 0 to 5, with 0 denoting perfect health and 5 indicating death. The 6 categories are 0=Asymptomatic (Fully active, able to carry on all predisease activities without restriction), 1=Symptomatic but completely ambulatory (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature), 2=Symptomatic, < 50% in bed during the day (Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours), 3=Symptomatic, > 50% in bed, but not bedbound (Capable of only limited self-care, confined to bed or chair 50% or more of waking hours), 4=Bedbound (Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair), 5=Death.
Measured: Baseline, Day 1 of every Cycle up to Clinical Data Cut (up to 48 months)
Hospitalization Days
Hospitalization was defined as a non-administration-related hospitalization due to serious adverse event, while on study treatment. Reported values represent number of days admitted per participants.
Measured: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014
Percentage of Participants With Hospitalization
Hospitalization was defined as a non-administration-related hospitalization due to serious adverse event, while on study treatment.
Measured: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014
Percentage of Participants With Objective Response According to IRF Assessment
Objective response was defined as having complete response (CR) or partial response (PR), assessed according to RECIST version 1.1, using radiographic images submitted to the IRF up to and including the confirmatory tumor assessment 4 to 6 weeks after study drug discontinuation. CR was defined as the disappearance of all target and non-target lesions and short-axis reduction in pathological lymph nodes to <10 mm. PR was defined as a ≥30% decrease in sum of diameters of target lesions, taking as reference the Baseline sum. Response was determined using 2 consecutive tumor assessments at least 4 weeks apart. The percentage of participants with a best overall response of CR or PR (ie, the objective response rate [ORR]) was calculated as [number of participants meeting the respective criteria divided by the number analyzed] multiplied by 100. Corresponding CIs were computed using the Blyth-Still-Casella exact method.
Measured: Up to 46 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
Percentage of Participants With Objective Response According to Investigator Assessment
Objective response was defined as having CR or PR, assessed according to RECIST version 1.1, by investigator. CR was defined as the disappearance of all target and non-target lesions and short-axis reduction in pathological lymph nodes to <10 mm. PR was defined as a ≥30% decrease in sum of diameters of target lesions, taking as reference the Baseline sum. Response was determined using 2 consecutive tumor assessments at least 4 weeks apart. The percentage of participants with a best overall response of CR or PR (ie, the ORR) was calculated as [number of participants meeting the respective criteria divided by the number analyzed] multiplied by 100. Corresponding CIs were computed using the Blyth-Still-Casella exact method.
Measured: Up to 46 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
Duration of Response According to IRF Assessment
Tumor assessments were performed according to RECIST version 1.1, using radiographic images submitted to the IRF up to and including the confirmatory tumor assessment 4 to 6 weeks after study drug discontinuation. Duration of response was defined as the time from confirmed PR or CR to first documented disease progression or death from any cause. CR was defined as the disappearance of all target lesions and non-target lesions and short-axis reduction in pathological lymph nodes to <10 mm. PR was defined as a ≥30% decrease in sum of diameters of target lesions, taking as reference the Baseline sum. Response was determined using 2 consecutive tumor assessments at least 4 weeks apart. Median duration of response was estimated using Kaplan-Meier analysis, and corresponding CIs were computed using the Brookmeyer-Crowley method.
Measured: Up to 46 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
Percentage of Participants With a Best Overall Response of CR, PR, or Stable Disease (SD) According to IRF Assessment
Tumor assessments were performed according to RECIST version 1.1, using radiographic images submitted to the IRF up to and including the confirmatory tumor assessment 4 to 6 weeks after study drug discontinuation. CR was defined as the disappearance of all target and non-target lesions and short-axis reduction in pathological lymph nodes to <10 mm. PR was defined as a ≥30% decrease in sum of diameters of target lesions, taking as reference the Baseline sum. SD was defined as neither sufficient shrinkage to quality for PR nor sufficient (20%) increase to qualify for disease progression. Response was determined using 2 consecutive tumor assessments at least 4 weeks apart. The percentage of participants with a best overall response of CR, PR, or SD was calculated as [number of participants meeting the respective criteria divided by the number analyzed] multiplied by 100.
Measured: Up to 46 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
Percentage of Participants Experiencing a Clinically Significant Increase in Taxane-Related Treatment Symptoms as Measured by Taxane Subscale of the Functional Assessment of Cancer Therapy (FACT) Taxane (FACT-TaxS) Score
The FACT-Taxane is a self-reported instrument which measures the health-related quality of life (HRQOL) of participants receiving taxane-containing chemotherapy. The FACT-TaxS consists of 16 items including 11 neurotoxicity-related questions and 5 additional questions assessing arthralgia, myalgia, and skin discoloration. Items are rated from 0 (not at all) to 4 (very much) and a total score is inversely derived. Scores may range from 0 to 64, with higher scores indicating fewer/no symptoms. A minimally clinically important difference in treatment-related symptoms was defined as a ≥5% decrease (ie, 3.2 points) in FACT-TaxS score from Baseline. The percentage of participants with treatment-related symptoms was calculated using following formula: [number of participants meeting the above threshold divided by the number analyzed] multiplied by 100. Corresponding CIs were computed using the Blyth-Still-Casella exact method.
Measured: Up to 39 months from randomization until clinical cutoff of 16-Sept-2014 (at Baseline, on Day 1 of Cycles 2 to 8 and every even-numbered cycle thereafter and/or up to 42 days after last dose)
Percentage of Participants Reporting Nausea According to the Relevant Single Items of The FACT Colorectal Cancel (FACT-C) Module
The FACT-C is a self-reported instrument which measures HRQOL pertaining to colorectal cancer. Response options on each question may range from 0 (not at all) to 4 (very much). The percentage of participants with nausea was calculated using following formula: [number of participants with any level of either symptom divided by the number analyzed] multiplied by 100.
Measured: At Baseline, Day 8 of Cycle 1, and Days 1 and 8 of Cycle 2
Percentage of Participants Reporting Diarrhea According to the Relevant Single Items of The FACT-C Module
The FACT-C is a self-reported instrument which measures HRQOL pertaining to colorectal cancer. Response options on each question may range from 0 (not at all) to 4 (very much). The percentage of participants with diarrhea was calculated using following formula: [number of participants with any level of either symptom divided by the number analyzed] multiplied by 100.
Measured: At Baseline, Day 8 of Cycle 1, and Days 1 and 8 of Cycle 2
Percentage of Participants With a Clinically Significant Deterioration in Health Related Quality of Life (HRQoL) as Measured by FACT Breast (FACT-B) Trial Outcome Index-Physical Function Breast (TOI-PFB) Score
The FACT-B is a self-reported instrument which measures HRQOL of participants with breast cancer. It consists of 5 subscales including physical well-being (PWB), social well-being (SWB), emotional well-being (EWB), functional well-being (FWB), and a breast cancer subscale (BCS). The TOI-PFB score is taken by adding the scores from the PWB (7 items), FWB (7 items), and BCS (9 items) subscales. Items are rated from 0 (not at all) to 4 (very much) and a total score is derived. Scores may range from 0 to 92, with higher scores indicating better HRQOL. A 5 point change has been identified as the clinically minimal important difference (CMID) on the FACT-TOI-PFB scale. The percentage of participants with deterioration was calculated as [number of participants meeting the above threshold divided by the number analyzed] multiplied by 100.
Measured: Up to 39 months from randomization until clinical cutoff of 16-Sept-2014 (at Baseline, on Day 1 of Cycles 2 to 8 and every even-numbered cycle thereafter and/or up to 42 days after last dose)
Time to Deterioration in HRQoL as Assessed by FACT-B TOI-PFB Score
The FACT-B is a self-reported instrument which measures HRQOL of participants with breast cancer. It consists of 5 subscales including PWB, SWB, EWB, FWB, and BCS. The TOI-PFB score is taken by adding the scores from the PWB (7 items), FWB (7 items), and BCS (9 items) subscales. Items are rated from 0 (not at all) to 4 (very much) and a total score is derived. Scores may range from 0 to 92, with higher scores indicating better HRQOL. A 5 point change has been identified as the clinically minimal important difference (CMID) on the FACT-TOI-PFB scale. Time to deterioration was defined as the time from Baseline until the first decrease in FACT-B TOI-PFB score. Median time to deterioration was estimated using Kaplan-Meier analysis, and corresponding CIs were computed using the Brookmeyer-Crowley method.
Measured: Baseline up to 39 months from randomization until clinical cutoff of 16-Sept-2014
Change From Baseline in Rotterdam Symptom Checklist (RSCL) Activity Level Scale Score
The RSCL is a self-reported instrument which consists of 4 domains including physical symptom distress, psychological distress, activity level, and overall global life quality. Only the activity level scale was collected and assessed. Scores may range from 0 to 100, with higher scores indicating increased burden of disease. Mean RSCL activity scale score changes were calculated as [mean score at the assessment visit minus mean score at Baseline]. The higher the score, the higher the level of impairment or burden.
Measured: Baseline, Cycle 7 (Week 18)
Change From Baseline in Work Productivity According to Work Productivity and Activity Impairment (WPAI) Questionnaire Score
The WPAI is a patient-reported measure which assesses the effect of general health and symptom severity on work productivity and regular activities. The General Health questionnaire asks participants to estimate the number of hours missed from work due to reasons related and unrelated to their health problems, as well as the total number of hours actually worked in the preceding 7-day period. The percentage of participants reporting that they were employed (working for pay) was assessed at baseline was assessed along with Absenteeism (work time missed), Presenteeism (impairment at work / reduced on-the-job effectiveness), Work productivity loss (overall work impairment / absenteeism plus presenteeism), and Activity Impairment. The reported changes represent change from baseline at Cycle 7. The score range for the scales of the WPAI is between 0 (no effect) to 100% (max effect)
Measured: Baseline, Cycle 7 (Week 18)
Change From Baseline in Activity Impairment According to Work Productivity and Activity Impairment (WPAI) Questionnaire Score
The WPAI is a patient-reported measure which assesses the effect of general health and symptom severity on work productivity and regular activities. The General Health questionnaire asks participants to estimate the number of hours missed from work due to reasons related and unrelated to their health problems, as well as the total number of hours actually worked in the preceding 7-day period. The percentage of participants reporting that they were employed (working for pay) was assessed at baseline was assessed along with Absenteeism (work time missed), Presenteeism (impairment at work / reduced on-the-job effectiveness), Work productivity loss (overall work impairment / absenteeism plus presenteeism), and Activity Impairment. The reported changes represent change from baseline at Cycle 7. The score range for the scales of the WPAI is between 0 (no effect) to 100% (max effect).
Measured: Baseline, Cycle 7 (Week 18)
Percentage of Participants With a Best Overall Response of CR or PR According to IRF Assessment Among Those With High Human Epidermal Growth Factor Receptor 2 (HER2) Messenger Ribonucleic Acid (mRNA) Levels
Tumor assessments were performed according to RECIST version 1.1, using radiographic images submitted to the IRF up to and including the confirmatory tumor assessment 4 to 6 weeks after study drug discontinuation. CR was defined as the disappearance of all target and non-target lesions and short-axis reduction in pathological lymph nodes to <10 mm. PR was defined as a ≥30% decrease in sum of diameters of target lesions, taking as reference the Baseline sum. Response was determined using 2 consecutive tumor assessments at least 4 weeks apart. The percentage of participants with a best overall response of CR or PR (ie, the ORR) was calculated as [number of participants meeting the respective criteria divided by the number analyzed] multiplied by 100.
Measured: Up to 46 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
Percentage of Participants With a Best Overall Response of CR or PR According to IRF Assessment Among Those With Low HER2 mRNA Levels
Tumor assessments were performed according to RECIST version 1.1, using radiographic images submitted to the IRF up to and including the confirmatory tumor assessment 4 to 6 weeks after study drug discontinuation. CR was defined as the disappearance of all target and non-target lesions and short-axis reduction in pathological lymph nodes to <10 mm. PR was defined as a ≥30% decrease in sum of diameters of target lesions, taking as reference the Baseline sum. Response was determined using 2 consecutive tumor assessments at least 4 weeks apart. The percentage of participants with a best overall response of CR or PR (ie, the ORR) was calculated as [number of participants meeting the respective criteria divided by the number analyzed] multiplied by 100.
Measured: Up to 46 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
Percentage of Participants With Death or Disease Progression According to IRF Assessment Among Those With High HER2 mRNA Levels
Tumor assessments were performed according to RECIST version 1.1, using radiographic images submitted to the IRF up to and including the confirmatory tumor assessment 4 to 6 weeks after study drug discontinuation. Disease progression was defined as a ≥20% and 5-mm increase in sum of diameters of target lesions, taking as reference the smallest sum obtained during the study, or appearance of new lesion(s). The percentage of participants with death or disease progression was calculated as [number of participants with event divided by the number analyzed] multiplied by 100.
Measured: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
PFS According to IRF Assessment Among Those With High HER2 mRNA Levels
Tumor assessments were performed according to RECIST version 1.1, using radiographic images submitted to the IRF up to and including the confirmatory tumor assessment 4 to 6 weeks after study drug discontinuation. PFS was defined as the time from randomization to first documented disease progression or death from any cause. Disease progression was defined as a ≥20% and 5-mm increase in sum of diameters of target lesions, taking as reference the smallest sum obtained during the study, or appearance of new lesion(s). Median duration of PFS was estimated using Kaplan-Meier analysis.
Measured: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
Percentage of Participants With Death or Disease Progression According to IRF Assessment Among Those With Low HER2 mRNA Levels
Tumor assessments were performed according to RECIST version 1.1, using radiographic images submitted to the IRF up to and including the confirmatory tumor assessment 4 to 6 weeks after study drug discontinuation. Disease progression was defined as a ≥20% and 5-mm increase in sum of diameters of target lesions, taking as reference the smallest sum obtained during the study, or appearance of new lesion(s). The percentage of participants with death or disease progression was calculated as [number of participants with event divided by the number analyzed] multiplied by 100.
Measured: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
PFS According to IRF Assessment Among Those With Low HER2 mRNA Levels
Tumor assessments were performed according to RECIST version 1.1, using radiographic images submitted to the IRF up to and including the confirmatory tumor assessment 4 to 6 weeks after study drug discontinuation. PFS was defined as the time from randomization to first documented disease progression or death from any cause. Disease progression was defined as a ≥20% and 5-mm increase in sum of diameters of target lesions, taking as reference the smallest sum obtained during the study, or appearance of new lesion(s). Median duration of PFS was estimated using Kaplan-Meier analysis.
Measured: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
Percentage of Participants Who Died Prior to Clinical Cutoff Among Those With High HER2 mRNA Levels
The percentage of participants who died prior to clinical cutoff was calculated as [number of participants with event divided by the number analyzed] multiplied by 100.
Measured: Up to 70 months from randomization until clinical cutoff of 15-May-2016 (every 3 months until death, loss to follow-up, withdrawal, or study termination)
OS at Clinical Cutoff Among Those With High HER2 mRNA Levels
OS was defined as the time from randomization to death from any cause. Median duration of OS was estimated using Kaplan-Meier analysis.
Measured: Up to 70 months from randomization until clinical cutoff of 15-May-2016 (every 3 months until death, loss to follow-up, withdrawal, or study termination)
Percentage of Participants Who Died Prior to Clinical Cutoff Among Those With Low HER2 mRNA Levels
The percentage of participants who died prior to clinical cutoff was calculated as [number of participants with event divided by the number analyzed] multiplied by 100.
Measured: Up to 70 months from randomization until clinical cutoff of 15-May-2016 (every 3 months until death, loss to follow-up, withdrawal, or study termination)
OS at Clinical Cutoff Among Those With Low HER2 mRNA Levels
OS was defined as the time from randomization to death from any cause. Median duration of OS was estimated using Kaplan-Meier analysis. Reported upper bound of confidence interval for "Trastuzumab Emtansine + Placebo" and confidence interval values for "Trastuzumab + Taxane" and "Trastuzumab Emtansine + Pertuzumab" are censored values.
Measured: Up to 70 months from randomization until clinical cutoff of 15-May-2016 (every 3 months until death, loss to follow-up, withdrawal, or study termination)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 May 2010 (estimated)
- Study start31 Jul 2010
- Primary completion30 Sep 2014
- Study completion16 Sep 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by Hoffmann-La RocheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 1,095 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Genentech, Inc.
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01120184
- Sponsor's protocol ID
- BO22589
- Other IDs
- 2009-017905-13, 2009
- Status last verified
- Feb 2024
- First submitted
- 28 Apr 2010
- Last updated
- 4 Mar 2024
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Publications
Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Stanzel S, Patre M, Ellis PA. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine +/- pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. BMC Cancer. 2019 May 30;19(1):517. doi: 10.1186/s12885-019-5687-0.
PubMed 31146717Bighin C, Pronzato P, Del Mastro L. Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients. Future Oncol. 2013 Jul;9(7):955-7. doi: 10.2217/fon.13.74.
PubMed 23837759Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012 Mar 22;12(4):278-87. doi: 10.1038/nrc3236.
PubMed 22437872
Study at a glance
From the registry record, last updated by the sponsor on 4 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, 3 Arm, Multicenter, Phase III Study to Evaluate the Efficacy and the Safety of T-DM1 Combined With Pertuzumab or T-DM1 Combined With Pertuzumab-Placebo (Blinded for Pertuzumab), Versus the Combination of Trastuzumab Plus Taxane, as First Line Treatment in HER2 Positive Progressive or Recurrent Locally Advanced or Metastatic Breast Cancer
- ClinicalTrials.gov ID
- NCT01120184
- Acronym / sponsor ID
- BO22589
- Conditions
- Breast Cancer
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,095 participants (actual)
- Lead sponsor
- Hoffmann-La RocheIndustry (pharma, biotech, devices)
- Collaborators
- Genentech, Inc.
- Study start
- 31 Jul 2010 (actual)
- Primary completion
- 30 Sep 2014 (actual)
- Study completion
- 16 Sep 2016 (actual)
- First posted
- 10 May 2010 (estimated)
- Results
- Posted 23 Feb 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized, 3-arm, multicenter, phase III study will evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) with pertuzumab or trastuzumab emtansine (T-DM1) with pertuzumab-placebo (blinded for pertuzumab), versus the combination of trastuzumab (Herceptin) plus taxane (docetaxel or paclitaxel) in participants with HER2-positive progressive or recurrent locally advanced or previously untreated metastatic breast cancer. Participants will be randomized to 1 of 3 treatment arms (Arms A, B or C). Arm A will be open-label, whereas Arms B and C will be blinded.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Trastuzumab + Taxane (docetaxel or paclitaxel) | Experimental | Drug: docetaxel, Drug: paclitaxel, Drug: trastuzumab [Herceptin] |
| Trastuzumab emtansine + pertuzumab | Experimental | Drug: pertuzumab, Drug: trastuzumab emtansine |
| Trastuzumab emtansine + pertuzumab placebo | Experimental | Drug: pertuzumab-placebo, Drug: trastuzumab emtansine |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Adult participants >/=18 years of age
- HER2-positive breast cancer
- Histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease, and be a candidate for chemotherapy. Participants with locally advanced disease must have recurrent or progressive disease, which must not be amenable to resection with curative intent.
- Participants must have measurable and/or non-measurable disease which must be evaluable per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
Key exclusion criteria (5 listed)
- History of prior (or any) chemotherapy for metastatic breast cancer or recurrent locally advanced disease
- An interval of <6 months from the last dose of vinca-alkaloid or taxane cytotoxic chemotherapy until the time of metastatic diagnosis
- Hormone therapy <7 days prior to randomization
- Trastuzumab therapy and/or lapatinib (neo- or adjuvant setting) <21 days prior to randomization
- Prior trastuzumab emtansine or pertuzumab therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| docetaxel75 mg/m2 or 100 mg/m2 intravenously every 3 weeks for a minimum of 6 cycles. | Drug | Trastuzumab + Taxane (docetaxel or paclitaxel) |
| paclitaxel80 mg/m2 intravenously weekly for a minimum of 18 weeks | Drug | Trastuzumab + Taxane (docetaxel or paclitaxel) |
| pertuzumab840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles | Drug | Trastuzumab emtansine + pertuzumab |
| pertuzumab-placebo840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles | Drug | Trastuzumab emtansine + pertuzumab placebo |
| trastuzumab [Herceptin]trastuzumab [Herceptin] doses when administered with docetaxel: 8 mg/kg intravenously on cycle 1 followed by 6 mg/kg every 3 weeks in subsequent cycles or trastuzumab (Herceptin) doses when administered with paclitaxel: 4 mg/kg intravenously on day 1 of cycle 1 followed by 2 mg/kg weekly starting on day 8 of cycle 1. | Drug | Trastuzumab + Taxane (docetaxel or paclitaxel) |
| trastuzumab emtansine3.6 mg/kg intravenously every 3 weeks | Drug | Trastuzumab emtansine + pertuzumab, Trastuzumab emtansine + pertuzumab placebo |
Primary outcome
Percentage of Participants With Death or Disease Progression According to Independent Review Facility (IRF) Assessment
Time frame: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
Tumor assessments were performed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, using radiographic images submitted to the IRF up to and including the confirmatory tumor assessment 4 to 6 weeks after study drug discontinuation. Disease progression was defined as a greater than or equal to (≥) 20 percent (%) and 5-millimeter (mm) increase in sum of diameters of target lesions, taking as reference the smallest sum obtained during the study, or appearance of new lesion(s). The percentage of participants with death or disease progression was calculated as [number of participants with event divided by the number analyzed] multiplied by 100.
Progression-Free Survival (PFS) According to IRF Assessment
Time frame: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
Tumor assessments were performed according to RECIST version 1.1, using radiographic images submitted to the IRF up to and including the confirmatory tumor assessment 4 to 6 weeks after study drug discontinuation. PFS was defined as the time from randomization to first documented disease progression or death from any cause. Disease progression was defined as a ≥20% and 5-mm increase in sum of diameters of target lesions, taking as reference the smallest sum obtained during the study, or appearance of new lesion(s). Median duration of PFS was estimated using Kaplan-Meier analysis, and corresponding confidence intervals (CIs) were computed using the Brookmeyer-Crowley method.
37 secondary outcomes
Percentage of Participants Who Died Prior to Clinical Cutoff
Time frame: Up to 70 months from randomization until clinical cutoff of 15-May-2016 (every 3 months until death, loss to follow-up, withdrawal, or study termination)
Overall Survival (OS) at Clinical Cutoff
Time frame: Up to 70 months from randomization until clinical cutoff of 15-May-2016 (every 3 months until death, loss to follow-up, withdrawal, or study termination)
Percentage of Participants With Death or Disease Progression According to Investigator Assessment
Time frame: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
PFS According to Investigator Assessment
Time frame: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
Percentage of Participants Experiencing Treatment Failure
Time frame: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014
Time to Treatment Failure (TTF)
Time frame: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014
One-Year Survival Rate
Time frame: From randomization until 1 year
Percentage of Participants With Grade ≥3 Adverse Events
Time frame: Up to 50 months from randomization until clinical cutoff of 16-Sept-2014 (continuously until 28 days after last dose
Percentage of Participants Who Died at 2 Years
Time frame: From randomization until 2 years
Overall Survival Truncated at 2 Years
Time frame: From randomization until 2 years
Percentage of Participants With Grade 5 Adverse Events
Time frame: Up to 50 months from randomization until clinical cutoff of 16-Sept-2014 (continuously until 28 days after last dose)
Percentage of Participants With Grade 3-4 Laboratory Parameters
Time frame: Day 1, 8, and 15 of Cycle 1-3 and on Day 1 of each subsequent cycle up to 50 months from randomization until clinical cutoff of 16-Sept-2014
Percentage of Participants With Decline of ≥2 Points From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status
Time frame: Baseline, Day 1 of every Cycle up to Clinical Data Cut (up to 48 months)
Hospitalization Days
Time frame: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014
Percentage of Participants With Hospitalization
Time frame: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014
Percentage of Participants With Objective Response According to IRF Assessment
Time frame: Up to 46 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
Percentage of Participants With Objective Response According to Investigator Assessment
Time frame: Up to 46 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
Duration of Response According to IRF Assessment
Time frame: Up to 46 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
Percentage of Participants With a Best Overall Response of CR, PR, or Stable Disease (SD) According to IRF Assessment
Time frame: Up to 46 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
Percentage of Participants Experiencing a Clinically Significant Increase in Taxane-Related Treatment Symptoms as Measured by Taxane Subscale of the Functional Assessment of Cancer Therapy (FACT) Taxane (FACT-TaxS) Score
Time frame: Up to 39 months from randomization until clinical cutoff of 16-Sept-2014 (at Baseline, on Day 1 of Cycles 2 to 8 and every even-numbered cycle thereafter and/or up to 42 days after last dose)
Percentage of Participants Reporting Nausea According to the Relevant Single Items of The FACT Colorectal Cancel (FACT-C) Module
Time frame: At Baseline, Day 8 of Cycle 1, and Days 1 and 8 of Cycle 2
Percentage of Participants Reporting Diarrhea According to the Relevant Single Items of The FACT-C Module
Time frame: At Baseline, Day 8 of Cycle 1, and Days 1 and 8 of Cycle 2
Percentage of Participants With a Clinically Significant Deterioration in Health Related Quality of Life (HRQoL) as Measured by FACT Breast (FACT-B) Trial Outcome Index-Physical Function Breast (TOI-PFB) Score
Time frame: Up to 39 months from randomization until clinical cutoff of 16-Sept-2014 (at Baseline, on Day 1 of Cycles 2 to 8 and every even-numbered cycle thereafter and/or up to 42 days after last dose)
Time to Deterioration in HRQoL as Assessed by FACT-B TOI-PFB Score
Time frame: Baseline up to 39 months from randomization until clinical cutoff of 16-Sept-2014
Change From Baseline in Rotterdam Symptom Checklist (RSCL) Activity Level Scale Score
Time frame: Baseline, Cycle 7 (Week 18)
Change From Baseline in Work Productivity According to Work Productivity and Activity Impairment (WPAI) Questionnaire Score
Time frame: Baseline, Cycle 7 (Week 18)
Change From Baseline in Activity Impairment According to Work Productivity and Activity Impairment (WPAI) Questionnaire Score
Time frame: Baseline, Cycle 7 (Week 18)
Percentage of Participants With a Best Overall Response of CR or PR According to IRF Assessment Among Those With High Human Epidermal Growth Factor Receptor 2 (HER2) Messenger Ribonucleic Acid (mRNA) Levels
Time frame: Up to 46 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
Percentage of Participants With a Best Overall Response of CR or PR According to IRF Assessment Among Those With Low HER2 mRNA Levels
Time frame: Up to 46 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
Percentage of Participants With Death or Disease Progression According to IRF Assessment Among Those With High HER2 mRNA Levels
Time frame: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
PFS According to IRF Assessment Among Those With High HER2 mRNA Levels
Time frame: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
Percentage of Participants With Death or Disease Progression According to IRF Assessment Among Those With Low HER2 mRNA Levels
Time frame: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
PFS According to IRF Assessment Among Those With Low HER2 mRNA Levels
Time frame: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)
Percentage of Participants Who Died Prior to Clinical Cutoff Among Those With High HER2 mRNA Levels
Time frame: Up to 70 months from randomization until clinical cutoff of 15-May-2016 (every 3 months until death, loss to follow-up, withdrawal, or study termination)
OS at Clinical Cutoff Among Those With High HER2 mRNA Levels
Time frame: Up to 70 months from randomization until clinical cutoff of 15-May-2016 (every 3 months until death, loss to follow-up, withdrawal, or study termination)
Percentage of Participants Who Died Prior to Clinical Cutoff Among Those With Low HER2 mRNA Levels
Time frame: Up to 70 months from randomization until clinical cutoff of 15-May-2016 (every 3 months until death, loss to follow-up, withdrawal, or study termination)
OS at Clinical Cutoff Among Those With Low HER2 mRNA Levels
Time frame: Up to 70 months from randomization until clinical cutoff of 15-May-2016 (every 3 months until death, loss to follow-up, withdrawal, or study termination)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Mar 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 31146717Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA 3rd, Stanzel S, Patre M, Ellis PA. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine +/- pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer. BMC Cancer. 2019 May 30;19(1):517. doi: 10.1186/s12885-019-5687-0.
- Derived from this study: PubMed 23837759Bighin C, Pronzato P, Del Mastro L. Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients. Future Oncol. 2013 Jul;9(7):955-7. doi: 10.2217/fon.13.74.
- Derived from this study: PubMed 22437872Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012 Mar 22;12(4):278-87. doi: 10.1038/nrc3236.
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Hoffmann-La Roche
257 sites in 38 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing docetaxel, paclitaxel and pertuzumab in people with Breast Cancer, run by Hoffmann-La Roche at 257 sites in 38 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 257 sites in United States, Japan, United Kingdom, Italy, France and 33 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 23 Feb 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With Death or Disease Progression According to Independent Review Facility (IRF) Assessment (time frame: Up to 48 months from randomization until clinical cutoff of 16-Sept-2014 (at Screening, every 9 weeks for 81 weeks, then every 12 weeks thereafter and/or up to 42 days after last dose)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01120184, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Mar 2024.